Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASH December 6, 2015
Affimed Presents Data Comparing T-cell- and NK-cell- engaging TandAbs AFM11 and AFM12 at ASH December 6, 2015
Affimed Announces Appointment of Andrew Curtis to Lead Corporate Strategy and Business Development, Expansion of US Presence December 2, 2015
Affimed Announces Third Quarter 2015 Financial Results and Corporate Update Conference Call November 3, 2015
